• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MCL1 as a therapeutic vulnerability in Burkitt lymphoma.

作者信息

Yuan Ren, Wang Michelle Y, Bi Chengfeng, Zhao Xiaohong, Tao Jianguo

机构信息

Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

出版信息

Leukemia. 2023 Apr;37(4):934-937. doi: 10.1038/s41375-023-01827-x. Epub 2023 Feb 2.

DOI:10.1038/s41375-023-01827-x
PMID:36732564
Abstract
摘要

相似文献

1
MCL1 as a therapeutic vulnerability in Burkitt lymphoma.MCL1作为伯基特淋巴瘤的一个治疗靶点。
Leukemia. 2023 Apr;37(4):934-937. doi: 10.1038/s41375-023-01827-x. Epub 2023 Feb 2.
2
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.一个过表达MCL1的伯基特淋巴瘤亚系在暴露于血清剥夺、拓扑异构酶抑制剂或星形孢菌素时表现出增强的存活率，但对1-β-D-阿拉伯呋喃糖基胞嘧啶仍敏感。
Cancer Res. 2002 Feb 1;62(3):892-900.
3
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.抗凋亡 MCL1 蛋白是大多数 Burkitt 淋巴瘤和 BCL2 阴性弥漫性大 B 细胞淋巴瘤的关键生存分子。
Mol Cancer Ther. 2022 Jan;21(1):89-99. doi: 10.1158/1535-7163.MCT-21-0511. Epub 2021 Nov 2.
4
[Malignant lymphoma. Physiopathology and therapy. 5. Burkitt lymphoma].[恶性淋巴瘤。病理生理学与治疗。5. 伯基特淋巴瘤]
Nihon Naika Gakkai Zasshi. 2008 Jul 10;97(7):1602-10. doi: 10.2169/naika.97.1602.
5
Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome.伴有复杂骨髓细胞遗传学改变的IV期成人散发性伯基特淋巴瘤/白血病预后极差。
Blood. 2009 Jul 9;114(2):485-6; author reply 486-7. doi: 10.1182/blood-2009-03-213231.
6
Antiproliferative and proapoptotic effects of extract on Burkitt lymphoma cell line.提取物对伯基特淋巴瘤细胞系的抗增殖和促凋亡作用。
Tumour Biol. 2020 Feb;42(2):1010428319901061. doi: 10.1177/1010428319901061.
7
Update on burkitt lymphoma and leukemia.伯基特淋巴瘤与白血病的最新进展
Clin Adv Hematol Oncol. 2009 Nov;7(11):728-9.
8
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.AZD3965对单羧酸转运体1的抑制作用作为弥漫性大B细胞淋巴瘤和伯基特淋巴瘤的一种新型治疗方法。
Haematologica. 2017 Jul;102(7):1247-1257. doi: 10.3324/haematol.2016.163030. Epub 2017 Apr 6.
9
Characteristics of new cell lines derived from Burkitt lymphomas.源自伯基特淋巴瘤的新细胞系的特征
Cancer. 1969 Jan;23(1):64-79. doi: 10.1002/1097-0142(196901)23:1<64::aid-cncr2820230107>3.0.co;2-m.
10
Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.1型人类嗜T淋巴细胞病毒携带者子宫的伯基特淋巴瘤
Intern Med. 2006;45(4):215-7. doi: 10.2169/internalmedicine.45.1381. Epub 2006 Mar 15.

本文引用的文献

1
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.BCL2 基因扩增缺失和转录重编程导致 B 细胞淋巴瘤模型对 ABT-199 耐药。
Cancer Cell. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005.
2
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.PLK1 在侵袭性 B 细胞淋巴瘤中稳定了一个依赖 MYC 的激酶网络。
J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5.
3
Survival control of malignant lymphocytes by anti-apoptotic MCL-1.
通过抗凋亡 MCL-1 控制恶性淋巴细胞的存活。
Leukemia. 2016 Nov;30(11):2152-2159. doi: 10.1038/leu.2016.213. Epub 2016 Aug 1.
4
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
5
Oncogenic mechanisms in Burkitt lymphoma.伯基特淋巴瘤的致癌机制。
Cold Spring Harb Perspect Med. 2014 Feb 1;4(2):a014282. doi: 10.1101/cshperspect.a014282.
6
Synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature.同步双侧乳腺癌合并腋窝非霍奇金淋巴瘤：一例报告及文献复习
Case Rep Oncol Med. 2012;2012:685919. doi: 10.1155/2012/685919. Epub 2012 Sep 23.
7
Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.通过基因组分析鉴定儿科和成人成熟 B 细胞非霍奇金淋巴瘤之间的分子差异。
Blood. 2012 Apr 19;119(16):3757-66. doi: 10.1182/blood-2011-05-349662. Epub 2012 Feb 28.
8
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.晚期、乳酸脱氢酶升高以及原发部位，但不是青少年年龄（≥15 岁），与成熟 B 细胞非霍奇金淋巴瘤患儿和青少年治疗失败风险增加相关：FAB LMB 96 研究结果。
J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3.
9
An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.荧光原位杂交检测到 13q 缺失频率增加及其对儿童和青少年伯基特淋巴瘤生存的影响：来自儿童肿瘤学组研究 CCG-5961 的结果。
Br J Haematol. 2010 Feb;148(4):600-10. doi: 10.1111/j.1365-2141.2009.07967.x. Epub 2009 Nov 4.
10
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).在德国高度恶性非霍奇金淋巴瘤研究组（DSHNHL）的随机试验中接受治疗的弥漫性大B细胞淋巴瘤中，影响MYC基因座的结构畸变表明预后不良，且独立于临床危险因素。
Leukemia. 2008 Dec;22(12):2226-9. doi: 10.1038/leu.2008.230. Epub 2008 Aug 28.